L3VLUP
ProSign in

RGNX in the 13F filings

Regenxbio Inc · CUSIP 75901B107

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023
Quarter end
30 Jun 2023
the date the book describes
Filed
11 Aug 2023
latest of these filings; the earliest 28 Jul 2023
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q1 2023 and Q2 2023; 0 listed it in both
Shares listed
490,601
combined, among listed positions
Reported value
$9.8m
combined, at the quarter end

Managers listing RGNX in Q2 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
ExodusPoint Capital Management LP490,601$9.8m0.08%Addedn.a.11 Aug 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2023 to Q2 2023, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (1)

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
4 in Q1 2024 to 1 in Q4 2025

Tracked managers listing it, at least.

0246201720182019202020212022202320242025
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
RGNX by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20161$742kn.a.n.a.
Q1 20172$2.5mn.a.n.a.
Q2 20172$7.7mn.a.n.a.
Q3 20173$19mn.a.n.a.
Q4 20172$7.8mn.a.n.a.
Q1 20183$5.1mn.a.n.a.
Q2 20186$34mn.a.n.a.
Q3 20185$36mn.a.n.a.
Q4 20181$373kn.a.n.a.
Q1 20192$11mn.a.n.a.
Q2 20193$11mn.a.n.a.
Q3 20191$3.2mn.a.n.a.
Q4 20192$12mn.a.n.a.
Q1 20203$12mn.a.n.a.
Q2 20204$21mn.a.n.a.
Q3 20203$17mn.a.n.a.
Q4 20203$6.0mn.a.n.a.
Q1 20212$33mn.a.n.a.
Q2 20211$2.0mn.a.n.a.
Q1 20222$17mn.a.n.a.
Q2 20223$15mn.a.n.a.
Q3 20222$998kn.a.n.a.
Q4 20223$13mn.a.n.a.
Q1 20232$5.8mn.a.n.a.
Q2 20231$9.8mn.a.n.a.
Q3 20232$10mn.a.n.a.
Q4 20231$1.6m01
Q1 20244$6.8m40
Q2 20243$3.2m11
Q3 20242$2.1m10
Q4 20242$1.3m10
Q1 20252$1.4m10
Q2 20251$1.2m10
Q3 20251$1.4m00
Q4 20251$2.9m1310

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

RGNX and GILD →RGNX and AMGN →RGNX and ARGX →Choose a stock to compare with RGNX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own RGNX, latest filings →Back to the 13F Explorer →